Thema: News: EGFR tyrosine kinase domain mutations in human gliomas.
News: EGFR tyrosine kinase domain mutations in human gliomas.
Katja[a]
06.05.2005 13:25:33
Neurology. 2005 Apr 26;64(8):1444-5
EGFR tyrosine kinase domain mutations in human gliomas.
Marie Y, Carpentier AF, Omuro AM, Sanson M, Thillet J, Hoang-Xuan K, Delattre JY.
Department of Neurology Mazarin and Institut National de la Sante et de la Recherche Medicale UMR-495, Paris, France.
Gefitinib is an epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor effective in patients with lung cancer with mutations in exons 19 and 21 of the EGFR tyrosine kinase domain. In this study, the authors tested the presence of such mutations in 95 gliomas including glioblastomas, anaplastic oligodendrogliomas, and low-grade gliomas. No mutation was found, which suggests that the biology of EGFR in gliomas is different from lung cancer and that this may be a factor in the resistance of glioblastomas to gefitinib.
EGFR tyrosine kinase domain mutations in human gliomas.
Marie Y, Carpentier AF, Omuro AM, Sanson M, Thillet J, Hoang-Xuan K, Delattre JY.
Department of Neurology Mazarin and Institut National de la Sante et de la Recherche Medicale UMR-495, Paris, France.
Gefitinib is an epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor effective in patients with lung cancer with mutations in exons 19 and 21 of the EGFR tyrosine kinase domain. In this study, the authors tested the presence of such mutations in 95 gliomas including glioblastomas, anaplastic oligodendrogliomas, and low-grade gliomas. No mutation was found, which suggests that the biology of EGFR in gliomas is different from lung cancer and that this may be a factor in the resistance of glioblastomas to gefitinib.
Katja[a]
